- $12.45m
- $3.86m
- $5.21m
Brief: Plus Therapeutics Regains Compliance With Applicable Nasdaq Listing Criteria
Brief: Plus Therapeutics Presents Positive Respect-LM Trial Results Of Reyobiq In Leptomeningeal Metastases
Plus Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Plus Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Plus Therapeutics Provides Us Launch Update For Its CNSide® Diagnostic
Brief: Plus Therapeutics Announces $1.6 Million Advance Payment From CPRIT
Brief: Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases
Brief: Plus Therapeutics Announces FDA Agreement To Initiate ReSPECT-LM Dose Optimization Trial For REYOBIQ In Leptomeningeal Metastases
U.S. STOCKS ON THE MOVE-Coinbase, Rubrik, AeroVironment
Plus Therapeutics jumps after FDA allows co to begin human trials for cancer therapy
Brief: Plus Therapeutics Announces FDA Clearance Of Its Investigational New Drug Application
Plus Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Plus Therapeutics Q1 Net Income USD -17.401 Million
Plus Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview
Plus Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview
Plus Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins Its Board Of Directors
Plus Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Plus Therapeutics FY Net Income USD -12.978 Million